SCHEMBL3081390

SCHEMBL3081390

Cc1n[nH]c(C)c1-c1cc(Cl)c(C#N)cc1F

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.38
KHK P50053 1/20 0.35
DHODH Q02127 1/20 0.35
AR P10275 1/20 0.34
EZH2 Q15910 1/20 0.34
CHEK1 O14757 1/20 0.34
AKT2 P31751 1/20 0.34
SCN9A Q15858 1/20 0.33
MET P08581 1/20 0.33
PROKR1 Q8TCW9 3/20 0.33
FPR2 P25090 2/20 0.33
AURKA O14965 1/20 0.33
TPX2 Q9ULW0 1/20 0.33
BRD4 O60885 1/20 0.32
EGLN2 Q96KS0 1/20 0.32
CYP11B2 P19099 1/20 0.32
PGK1 P00558 1/20 0.32
IKBKB O14920 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3081398 0.75 CHEK1 (0.37) DHODHARCHEK1AKT2SCN9A
SCHEMBL3075841 0.74 IKBKB (0.49) CHEK1AKT2AURKATPX2BRD4
SCHEMBL3076212 0.74 IKBKB (0.49) ARCHEK1AKT2AURKACYP11B2
SCHEMBL3080716 0.71 CYP11B1 (0.50) CHEK1AKT2EGLN2CYP11B2
SCHEMBL10873741 0.70 MET (0.39) ALDH1A1METBRD4
SCHEMBL111483 0.70 CHEK1 (0.51) ALDH1A1CHEK1AKT2SCN9AAURKA
SCHEMBL17520012 0.68 ALDH1A1 (0.46) ALDH1A1KHKAREGLN2CYP11B2
SCHEMBL3074111 0.68 AR (0.36) ALDH1A1AREZH2CHEK1AKT2
SCHEMBL3336692 0.67 ALDH1A1 (0.51) ALDH1A1KHKARCYP11B2PGK1
SCHEMBL24752497 0.67 ADORA2A (0.44) ALDH1A1PROKR1FPR2PGK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-09 US disclosed
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-09 US disclosed
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-09 US disclosed
EP-2194045-A1 SUBSTITUTED PYRAZOLE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2010-06-09 EP disclosed
EP-2194045-A1 SUBSTITUTED PYRAZOLE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2010-06-09 EP disclosed
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE AR, NR5A1, NR3C2 ALDH1A1 809/4885KHK 2976/4885DHODH 1683/4885
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES AR, NR5A1, NR3C2 ALDH1A1 816/4885KHK 3025/4885DHODH 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.